不眠症薬理学的治療市場：薬剤、治療法、流通チャネル別-2025-2030年の世界予測

不眠症薬理学的治療市場は、2023年に65億8,000万米ドルと評価され、2024年には70億1,000万米ドルに達すると予測され、CAGR 7.07％で成長し、2030年には106億2,000万米ドルに達すると予測されています。

不眠症薬理学的治療の対象範囲には、入眠障害や睡眠維持障害を特徴とする不眠を管理するために使用される処方薬や市販薬が主に含まれます。これらの治療は、精神的・身体的健康に悪影響を及ぼし、生活の質を低下させる不眠症の高い有病率のために必要です。その用途は、病院、診療所、小売薬局など、さまざまな最終用途に及んでおり、成人が使用することが多く、高齢者人口の使用も増えています。市場に影響を与える主な成長要因としては、ストレスレベルの上昇、老年人口の増加、メンタルヘルスに対する意識の高まり、副作用の少ない薬物療法の進歩などが挙げられます。さらに、患者管理を支援するデジタルヘルスツールの登場は、治療の有効性とカスタマイズ性を高める潜在的な機会を提示しています。独自の作用機序を持ち、依存性の少ない薬剤の開発や、AIを活用した個別化医療のアプローチには機会があふれています。しかし、長期投薬による副作用、規制上の課題、認知行動療法のような代替非薬物療法など、市場成長は限界に直面しています。さらに、一部の不眠症治療薬の乱用や依存の可能性は喫緊の懸念事項です。この分野における技術革新は、より安全で習慣性のない選択肢を開発すること、バイオテクノロジーを活用して特定の神経伝達物質をよりよく標的とする薬剤を開発することを中心に展開されています。不眠症に関連する疾患の複雑性を理解するための調査は、画期的な進歩をもたらす肥沃な土壌を提供しています。この市場は、既存大手製薬企業と新興バイオベンチャー企業の両方が新規治療薬の研究をリードする、ダイナミックで競合情勢に特徴があります。デジタルヘルスプラットフォームとの連携も、全人的な不眠症管理への重要な傾向を示しており、医療と技術進歩の相乗効果を浮き彫りにしています。市場でのリーダーシップを目指す企業は、規制状況や臨床試験状況を効果的にナビゲートしながら、こうした新たな科学的・技術的動向に焦点を当てた研究開発投資を優先すべきです。

市場力学：急速に進化する不眠症薬理学的治療市場の主要市場インサイトを公開

不眠症薬理学的治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 不眠症や睡眠時随伴症など、さまざまなタイプの睡眠障害の有病率の上昇
  • 仕事に関連したストレスレベルと身体障害の急増
  • 患者の意識の高まりによる不眠症に関する受診の増加
• 市場抑制要因
  • 特定のOTC薬や処方薬に伴う副作用
• 市場機会
  • 効率的な研究開発活動による新規製品の開発
  • 睡眠の質を改善する非薬物療法の進歩
• 市場の課題
  • 一部の患者における不眠症に対する個人レベルの偏見

ポーターの5つの力：不眠症薬理学的治療市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：不眠症薬理学的治療市場における外部からの影響の把握

外部マクロ環境要因は、不眠症薬理学的治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析不眠症薬理学的治療市場における競合情勢の把握

不眠症薬理学的治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス不眠症薬理学的治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、不眠症薬理学的治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨不眠症薬理学的治療市場における成功への道筋を描く

不眠症薬理学的治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品上市、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 不眠症や睡眠障害など、さまざまな睡眠障害の罹患率が上昇している
    • 仕事関連のストレスレベルと身体障害の急増
    • 患者の意識の高まりにより不眠症に関する医師の診察が増加
  • 抑制要因
    • 特定の市販薬や処方薬に伴う副作用
  • 機会
    • 効率的な研究開発活動による新製品の開発
    • 睡眠の質を改善する非薬物療法の進歩
  • 課題
    • 一部の患者における不眠症に関する個人レベルの偏見
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 不眠症薬理学的治療市場薬物別

• 市販薬
• 市販の睡眠補助薬
• 市販の睡眠サプリメント
• 処方薬

第7章 不眠症薬理学的治療市場治療別

• 市販の睡眠補助薬
  • 抗ヒスタミン薬
  • メラトニン
  • バレリアンの根
• 処方睡眠補助薬
  • ベンゾジアゼピン
  • メラトニン受容体拮抗薬
  • 非ベンゾジアゼピン
    • エスゾピクロン
    • ザレプロン
    • ゾルピデム
  • オレキシン拮抗薬

第8章 不眠症薬理学的治療市場：流通チャネル別

• ドラッグストア
• eコマース
• 病院薬局
• 小売薬局

第9章 南北アメリカの不眠症薬理学的治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の不眠症薬理学的治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの不眠症薬理学的治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Aa Pharma Inc.
• Amneal Pharmaceuticals LLC
• BlaQmax by Akay Natural Ingredients Private Limited
• Dr. Reddy's Laboratories
• Eisai Co., Ltd.
• Fresenius Kabi AG
• Gemini Pharmaceuticals
• Idorsia Pharmaceuticals Ltd.
• Ingenus Pharmaceuticals
• Makers Nutrition, LLC
• Merck & Co., Inc.
• Micro Labs Limited
• Paratek Pharmaceuticals, Inc.
• Pfizer Inc.
• Purdue Pharma L.P.
• Sanofi S.A.
• Sivem Pharmaceuticals ULC
• Sleepme Inc.
• SMP Nutra
• Sumitomo Pharma Co., Ltd.
• Takeda Pharmaceuticals Company Ltd.
• TriVue Pharmaceuticals, Inc.
• Tru Body Wellness
• Vanda Pharmaceuticals
• Vera Herbals LLC
• Viatris Inc.

LIST OF FIGURES

• FIGURE 1. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OTC DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OTC SLEEP AIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OTC SLEEP SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY VALERIAN ROOTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESZOPICLONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZALEPLON, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. CANADA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 53. CANADA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 54. CANADA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 55. CANADA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 56. CANADA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 57. CANADA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 78. AUSTRALIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 79. AUSTRALIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 80. AUSTRALIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. CHINA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 85. CHINA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 86. CHINA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 87. CHINA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 88. CHINA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 89. CHINA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. INDIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 91. INDIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 92. INDIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 93. INDIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 94. INDIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 95. INDIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. INDONESIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 97. INDONESIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 98. INDONESIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. JAPAN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 103. JAPAN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 104. JAPAN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 108. MALAYSIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 109. MALAYSIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 110. MALAYSIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 114. PHILIPPINES INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 115. PHILIPPINES INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 116. PHILIPPINES INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 120. SINGAPORE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 121. SINGAPORE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 122. SINGAPORE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH KOREA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH KOREA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 132. TAIWAN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 133. TAIWAN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 134. TAIWAN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. THAILAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 139. THAILAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 140. THAILAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. VIETNAM INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 145. VIETNAM INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 146. VIETNAM INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 150. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 157. DENMARK INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 158. DENMARK INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 159. DENMARK INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 163. EGYPT INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 164. EGYPT INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 165. EGYPT INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 169. FINLAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 170. FINLAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 171. FINLAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 175. FRANCE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 176. FRANCE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 177. FRANCE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 181. GERMANY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 182. GERMANY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 183. GERMANY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 187. ISRAEL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 188. ISRAEL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 189. ISRAEL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 193. ITALY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 194. ITALY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 195. ITALY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 196. ITALY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 197. ITALY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 198. ITALY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 199. NETHERLANDS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 200. NETHERLANDS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 201. NETHERLANDS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 205. NIGERIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 206. NIGERIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 207. NIGERIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 211. NORWAY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 212. NORWAY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 213. NORWAY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 217. POLAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 218. POLAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 219. POLAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 220. POLAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 221. POLAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 222. POLAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 223. QATAR INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 224. QATAR INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 225. QATAR INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 226. QATAR INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 227. QATAR INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 228. QATAR INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 229. RUSSIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 230. RUSSIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 231. RUSSIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 235. SAUDI ARABIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 236. SAUDI ARABIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 241. SOUTH AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 242. SOUTH AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 247. SPAIN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 248. SPAIN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 249. SPAIN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 253. SWEDEN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 254. SWEDEN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 255. SWEDEN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 259. SWITZERLAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 260. SWITZERLAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 261. SWITZERLAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 265. TURKEY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 266. TURKEY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 267. TURKEY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 271. UNITED ARAB EMIRATES INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 272. UNITED ARAB EMIRATES INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 277. UNITED KINGDOM INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 278. UNITED KINGDOM INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OVER-THE-COUNTER SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRESCRIPTION SLEEP AIDS, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 283. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 284. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Insomnia Pharmacological Treatment Market was valued at USD 6.58 billion in 2023, expected to reach USD 7.01 billion in 2024, and is projected to grow at a CAGR of 7.07%, to USD 10.62 billion by 2030.

The scope of insomnia pharmacological treatment primarily includes prescription and over-the-counter medications used to manage sleeplessness, characterized by difficulty in falling asleep or maintaining sleep. These treatments are necessary due to the high prevalence of insomnia, which can adversely affect mental and physical health and diminish the quality of life. Their application spans various end-users, including hospitals, clinics, and retail pharmacies, often used by adults and increasingly by the elderly population. Key growth factors influencing the market include rising stress levels, a growing geriatric populace, increasing awareness about mental health, and advances in medication with fewer side effects. Moreover, the advent of digital health tools that assist in patient management presents a potential opportunity for enhancing treatment efficacy and customization. Opportunities abound in developing medications with unique mechanisms of action and fewer dependencies, as well as leveraging AI for personalized medicine approaches. However, the market growth faces limitations from the side effects of long-term medication use, regulatory challenges, and alternative non-pharmacological treatments like cognitive behavioral therapy. Furthermore, the potential for abuse or dependency on some insomnia medications is a pressing concern. Innovation in this area revolves around developing safer, non-habit-forming options and leveraging biotechnology to create drugs that target specific neurotransmitters better. Research into understanding the complexities of insomnia-associated disorders offers fertile ground for breakthroughs. The market is characterized by a dynamic and competitive landscape with both established pharmaceutical giants and emerging biotech startups leading research in novel therapeutics. Cooperation with digital health platforms also signals a significant trend towards holistic insomnia management, highlighting the synergy between medical treatment and technological advancement. Companies aiming for market leadership should prioritize R&D investments focused on these emerging scientific and technological trends while navigating through the regulatory and clinical trial landscape effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Insomnia Pharmacological Treatment Market

The Insomnia Pharmacological Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of different types of sleep disorders including insomnia and parasomnias
  • Surge in work related stress level and physical disorders
  • Increasing visits to doctor regarding to insomnia owing to rising awareness among patients
• Market Restraints
  • Side effects associated with certain OTC and prescription medication
• Market Opportunities
  • Development of novel products through efficient R&D activities
  • Advancement in non-pharmacological therapy to improve sleep quality
• Market Challenges
  • Individual level stigma about insomnia in some patients

Porter's Five Forces: A Strategic Tool for Navigating the Insomnia Pharmacological Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Insomnia Pharmacological Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Insomnia Pharmacological Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Insomnia Pharmacological Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Insomnia Pharmacological Treatment Market

A detailed market share analysis in the Insomnia Pharmacological Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Insomnia Pharmacological Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Insomnia Pharmacological Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Insomnia Pharmacological Treatment Market

A strategic analysis of the Insomnia Pharmacological Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Insomnia Pharmacological Treatment Market, highlighting leading vendors and their innovative profiles. These include Aa Pharma Inc., Amneal Pharmaceuticals LLC, BlaQmax by Akay Natural Ingredients Private Limited, Dr. Reddy's Laboratories, Eisai Co., Ltd., Fresenius Kabi AG, Gemini Pharmaceuticals, Idorsia Pharmaceuticals Ltd., Ingenus Pharmaceuticals, Makers Nutrition, LLC, Merck & Co., Inc., Micro Labs Limited, Paratek Pharmaceuticals, Inc., Pfizer Inc., Purdue Pharma L.P., Sanofi S.A., Sivem Pharmaceuticals ULC, Sleepme Inc., SMP Nutra, Sumitomo Pharma Co., Ltd., Takeda Pharmaceuticals Company Ltd., TriVue Pharmaceuticals, Inc., Tru Body Wellness, Vanda Pharmaceuticals, Vera Herbals LLC, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Insomnia Pharmacological Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug, market is studied across OTC Drugs, OTC Sleep Aids, OTC Sleep Supplements, and Prescription Drugs.
• Based on Treatment, market is studied across Over-the-Counter Sleep Aids and Prescription Sleep Aids. The Over-the-Counter Sleep Aids is further studied across Antihistamines, Melatonin, and Valerian Roots. The Prescription Sleep Aids is further studied across Benzodiazepines, Melatonin Receptor Antagonists, Non-benzodiazepines, and Orexin Antagonists. The Non-benzodiazepines is further studied across Eszopiclone, Zaleplon, and Zolpidem.
• Based on Distribution Channel, market is studied across Drug Stores, E-Commerce, Hospital Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of different types of sleep disorders including insomnia and parasomnias
    • 5.1.1.2. Surge in work related stress level and physical disorders
    • 5.1.1.3. Increasing visits to doctor regarding to insomnia owing to rising awareness among patients
  • 5.1.2. Restraints
    • 5.1.2.1. Side effects associated with certain OTC and prescription medication
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of novel products through efficient R&D activities
    • 5.1.3.2. Advancement in non-pharmacological therapy to improve sleep quality
  • 5.1.4. Challenges
    • 5.1.4.1. Individual level stigma about insomnia in some patients
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Insomnia Pharmacological Treatment Market, by Drug

• 6.1. Introduction
• 6.2. OTC Drugs
• 6.3. OTC Sleep Aids
• 6.4. OTC Sleep Supplements
• 6.5. Prescription Drugs

7. Insomnia Pharmacological Treatment Market, by Treatment

• 7.1. Introduction
• 7.2. Over-the-Counter Sleep Aids
  • 7.2.1. Antihistamines
  • 7.2.2. Melatonin
  • 7.2.3. Valerian Roots
• 7.3. Prescription Sleep Aids
  • 7.3.1. Benzodiazepines
  • 7.3.2. Melatonin Receptor Antagonists
  • 7.3.3. Non-benzodiazepines
    • 7.3.3.1. Eszopiclone
    • 7.3.3.2. Zaleplon
    • 7.3.3.3. Zolpidem
  • 7.3.4. Orexin Antagonists

8. Insomnia Pharmacological Treatment Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Drug Stores
• 8.3. E-Commerce
• 8.4. Hospital Pharmacies
• 8.5. Retail Pharmacies

9. Americas Insomnia Pharmacological Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Insomnia Pharmacological Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Insomnia Pharmacological Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Aa Pharma Inc.
• 2. Amneal Pharmaceuticals LLC
• 3. BlaQmax by Akay Natural Ingredients Private Limited
• 4. Dr. Reddy's Laboratories
• 5. Eisai Co., Ltd.
• 6. Fresenius Kabi AG
• 7. Gemini Pharmaceuticals
• 8. Idorsia Pharmaceuticals Ltd.
• 9. Ingenus Pharmaceuticals
• 10. Makers Nutrition, LLC
• 11. Merck & Co., Inc.
• 12. Micro Labs Limited
• 13. Paratek Pharmaceuticals, Inc.
• 14. Pfizer Inc.
• 15. Purdue Pharma L.P.
• 16. Sanofi S.A.
• 17. Sivem Pharmaceuticals ULC
• 18. Sleepme Inc.
• 19. SMP Nutra
• 20. Sumitomo Pharma Co., Ltd.
• 21. Takeda Pharmaceuticals Company Ltd.
• 22. TriVue Pharmaceuticals, Inc.
• 23. Tru Body Wellness
• 24. Vanda Pharmaceuticals
• 25. Vera Herbals LLC
• 26. Viatris Inc.